Shuttle Pharmaceuticals Holdings Inc (SHPH) Directors and Executive Officers

Officers & Directors

Joshua Schafer
Director

Milton Brown
Director

Bette Jacobs
Director

Anatoly Dritschilo, M.D.
Chairman of the Board of Directors, Chief Executive Officer and President

Chris H. Senanayake
Director

Michael Vander Hoek
Chief Financial Officer (Principal Financial and Accounting Officer)

Steven Richards
Director

BF Borgers CPA PC
Served as Auditor

FORVIS, LLP
Served as the Company’s auditor since ,

Shuttle Pharmaceuticals Holdings Inc currently has 2 employees.

News about Shuttle Pharmaceuticals Holdings Inc Key Personnel

Shuttle Pharmaceuticals Reports Financial Struggles Amid Focus on Cancer Treatments

In a recent corporate update, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) revealed a challenging financial landscape as it navigates the complexities of the oncology market. The Gaithersburg, Maryland-based company, known for its commitment to enhancing outcomes for cancer patients undergoing radiation therapy, reported a notable decline in its stock value and significant net losses for the period ending September 30, 2024.During the month of November, the company s shares plummeted by 19.16%, reflecting investor concerns over its financial viability and market performance. The quarterly report indicated an alarming cumulative net loss of $7 million over the twelve months leading into the second qu...

Shuttle Pharma Pays Off Senior Secured Convertible Note

Shuttle Pharmaceuticals Advances Strategic Goals through Debt Payoff and New Public OfferingIn a notable demonstration of fiscal responsibility and strategic growth, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a Maryland-based specialty pharmaceutical company dedicated to improving outcomes for cancer patients undergoing radiation therapy, has recently completed significant financial maneuvers. On October 29, 2024, the company announced it has fully paid off its Senior Secured Convertible Note, originally issued on January 11, 2023. This decisive action reflects Shuttle Pharma’s commitment to maintaining a strong fiscal foundation while concurrently paving the way for future clinical advancemen...